secwatch.observer — SEC 8-K summary
======================================

Issuer:     Denali Therapeutics Inc. (DNLI)
CIK:        0001714899
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001714899-22-000143
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Denali Q3 net loss widens to $103.3M; cash at $1.11B after $296M offering
-------------------------------------------------------------------------

- Net loss of $103.3M for Q3 2022 vs. $84.6M in Q3 2021; collaboration revenue fell to $3.6M from $5.3M.
- R&D expenses rose to $87.8M (up $16.2M) driven by LRRK2 milestone payment and pipeline progress.
- Cash, cash equivalents, and marketable securities totaled $1.11B as of Sep 30, 2022, plus net proceeds of $296.2M from Oct 2022 public offering.
- Phase 3 LIGHTHOUSE study of BIIB122 initiated in LRRK2-positive Parkinson's; Phase 2 COMPASS study of DNL310 enrolling in Hunter syndrome.
- Interim Phase 1 data for TAK-594/DNL593 showed substantial CSF progranulin increases supporting FTD-GRN Part B dosing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1714899/000171489922000143/0001714899-22-000143-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1714899/000171489922000143/dnli-20221103.htm
  HTML page:      https://secwatch.observer/filing/0001714899-22-000143

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer